MML Investors Services LLC Purchases 2,218 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

MML Investors Services LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 41.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,533 shares of the biopharmaceutical company's stock after acquiring an additional 2,218 shares during the quarter. MML Investors Services LLC's holdings in Regeneron Pharmaceuticals were worth $5,366,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Pamalican Asset Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $4,915,000. Intact Investment Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $356,000. Rhenman & Partners Asset Management AB lifted its holdings in Regeneron Pharmaceuticals by 11.4% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after buying an additional 4,457 shares during the period. Principal Financial Group Inc. boosted its position in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Finally, Fagan Associates Inc. grew its holdings in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after purchasing an additional 3,832 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on REGN shares. Bernstein Bank decreased their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Sanford C. Bernstein reduced their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Finally, TD Cowen cut their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $941.12.

Regeneron Pharmaceuticals Trading Up 1.9 %

REGN stock traded up $10.58 during midday trading on Wednesday, reaching $579.49. 348,138 shares of the company's stock traded hands, compared to its average volume of 734,227. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The company has a market capitalization of $63.35 billion, a P/E ratio of 15.14, a PEG ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business has a 50-day moving average price of $633.34 and a two-hundred day moving average price of $718.04.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $9.55 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.61%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.